Print
Email
Print Edition StoriesVideo Gallery
Funding drugs for rare diseases
MHT's Marc Songini: RI plans launch of cord blood center
Rodney Brown on NECN: Hacking into medical devices
Boston Scientific Corp. on Monday said European regulators have approved its Promus Element stent — the latest version of the company’s drug-coated stent technology meant to prop open previously clogged arteries.
The new Promus Element stents replace the current stents, which were made under an agreement that Boston Scientific (NYSE: BSX) has with Abbott Laboratories (NYSE: ABT). That agreement is set to expire soon.
Natick-based Boston Scientific will begin marketing the Promus Element system immediately in the European Union. The company says the Promus Element includes innovations including a proprietary platinum chromium alloy that has greater strength and flexibility than older alloys.
RSS Feeds
Comments
Please Login/Register to post comments.
No comments have been added or approved.